The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

BACKGROUND: Improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity including signalling through PD1/PD-L1 and LAG3/MHC-II. METHODS: CB213 has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Carolyn J., Sette, Angelica, Cox, Carl, Di Fiore, Barbara, Wyre, Chris, Sydoruk, Daniela, Yadin, David, Hayes, Philip, Stelter, Szymon, Bartlett, Phillip D., Zuazo, Miren, Garcia-Granda, Maria Jesus, Benedetti, Giovanni, Fiaska, Stratoniki, Birkett, Neil R., Teng, Yumin, Enever, Carrie, Arasanz, Hugo, Bocanegra, Ana, Chocarro, Luisa, Fernandez, Gonzalo, Vera, Ruth, Archer, Bethan, Osuch, Isabelle, Lewandowska, Martyna, Surani, Yasmin M., Kochan, Grazyna, Escors, David, Legg, James, Pierce, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023588/
https://www.ncbi.nlm.nih.gov/pubmed/34969998
http://dx.doi.org/10.1038/s41416-021-01684-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023588/
https://www.ncbi.nlm.nih.gov/pubmed/34969998
http://dx.doi.org/10.1038/s41416-021-01684-4

Ejemplares similares